Skip to Main Content

E3303/SCCC 2005009: Phase II Study of C225 (Erbitux or Cetuximab) In Combination with Cisplatin and Definitive Radiation in Unresectable Stage 4 Squamos Cell Carcinoma of the Head and Neck

Principal Investigator

Khaled Tolba

Clinical Trial ID

Institutional Protocol # 20101068

Clinical Trial Summary


Phase II

Funding Agency/Sponsor

National Cooperative Group


Head and Neck Cancer

Contact Information

Phone Number 305-243-2647